Etoposide plus benmelstobart then maintenance with benmelstobart and anlotinib for elderly patients with extensive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of chemotherapy (etoposide), immunotherapy (benmelstobart), and a targeted drug (anlotinib) as the first treatment for older adults (ages 70–85) with extensive-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and delay growth with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were just diagnosed with extensive-stage small cell lung cancer and have not had any treatment for it yet.
- You are between 70 and 85 years old.
- Your overall health is fairly good (score of 0, 1, or 2 on the ECOG scale – you can take care of yourself, though you may need some rest).
- Your blood counts, liver and kidney function, and heart pump strength meet the trial’s minimum safe levels.
- You have at least one tumor that can be seen on a CT scan, and your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding a targeted therapy called anlotinib to immunotherapy maintenance can help people with extensive-stage small cell lung cancer who have already completed 4-6 cycles of standard chemoimmunotherapy without the cancer getting worse.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This study tests a combination of three drugs (bevacizumab, anlotinib, and etoposide) as a first treatment for patients with metastatic small-cell lung cancer who are 65 or older, or who cannot tolerate standard intensive chemotherapy. The goal is to see if this gentler approach can effectively control the cancer while being safer for these patients.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This study tests a new combination of drugs (Benmelstobart immunotherapy plus chemotherapy, with or without Anlotinib) before surgery for people with limited-stage small cell lung cancer. The goal is to see if these drugs help shrink the tumor and improve outcomes.
Hear when a new ELDERLY PEOPLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.